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Bladder cancerWe have previously reported that synthetic dsRNA can activate p21 expression by targeting the p21
promoter, thereby suppressing the proliferation of human bladder cancer cells. As complementarity
between dsRNA and its target sequences is necessary for RNA activation, miRNAs may also trigger
p21 expression through the same mechanism. Here, the expression levels of three miRNAs (miR-
370, miR-1180 and miR-1236) decreased in bladder cancer tissues compared to healthy controls
and the levels of these mRNAs positively correlated with p21 mRNA levels. The three miRNAs
induced nuclear p21 expression through p21-promoter binding. Overexpression of the three miR-
NAs inhibited the proliferation of bladder cancer cells mainly by regulating p21. Therefore, these
miRNAs could be candidates for anti-cancer drugs.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Bladder cancer (BC) represents the sixth most common cancer
and the second most common cause of death in patients with gen-
itourinary tract malignancies worldwide [1]. Although there have
been many signiﬁcant advances in therapies, including surgical
resection, radiotherapy and chemotherapy, high recurrence and
progression rates still persist resulting in poor prognosis of BC [1].
MicroRNAs (miRNAs) are small endogenous non-coding RNAs
with approximately 19–24 nucleotides that regulate target genes
post-transcriptionally [2]. Evidence shows that miRNAs play
important roles in tumor growth, apoptosis and metastasis [3].
There are many studies demonstrating that miRNAs hold the
capacity to repress mRNA translation by recognizing complemen-
tary sequences in the 30 untranslated regions (UTRs), 50 UTRs or
open reading frame [4–6]. However, miRNAs could upregulate spe-
ciﬁc genes expression by targeting promoters [7,8]. The underlying
mechanism was similar to RNA activation (RNAa) – synthetic dou-
ble-stranded RNAs (dsRNAs) induce sequence-speciﬁc gene
expression by targeting promoter [9].
p21WAF1/CIP1 (p21) is a multifunctional protein and a key medi-
ator in regulating different cellular processes [10]. As aberrantexpression of p21 leads to the development of tumor, gain-of-func-
tion manipulation of p21 is an ideal strategy to inhibit cancer cell
growth. Moreover, the subcellular localization is also responsible
for its anti-tumor effects. p21 functions as a tumor suppressor
when localized in the nucleus, and as an oncogene through its
cytoplasmic translocation [11].
Our previous study had shown that dsRNAs transfection had
anti-tumor activity by activating p21 expression in BC cell lines
[12]. To determine whether miRNAs can also positively affect
p21, we scanned the p21 promoter sequences and identiﬁed multi-
ple putative sites highly complementary to knownmiRNAs. Several
miRNAs with higher alignment scores were selected and transfec-
ted into human BC cells. The anti-tumor effect of p21 activated by
proper miRNAs was further investigated. Our results revealed an
endogenous function of miRNAs in speciﬁc gene activation and
cancer cell suppression.
2. Materials and methods
2.1. Tissue samples
Ten paired BC tissues and adjacent non-tumor bladder mucosal
tissues were obtained from patients undergoing radical cystec-
tomy. The samples were collected between Jan 2014 and June
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University of Science and Technology (Wuhan, China) after
informed consent and Ethics Committee’s approval. Tissue samples
were trimmed and cryopreserved in liquid nitrogen for further
analysis.
2.2. Target miRNAs prediction
Target miRNAs complementary to p21 gene promoter were pre-
dicted by the miRanda program running on Linux operating sys-
tem, as previously described [8]. One kilobase of the human p21
promoter sequence was retrieved from the Ensembl genome data-
base (www.ensembl.org), and human miRNA sequences were
retrieved from miRBase (www.mirbase.org). Putative target sites
were identiﬁed by scanning the p21 promoter sequence against
all known miRNAs. An alignment score of 160 and minimum free
energy of 22 kcal/mol were set as the positive prediction thresh-
old. Moreover, all selected miRNAs possessed no putative target
sites in 30 or 50 UTR of the p21 transcript.
2.3. dsRNA and miRNA
All dsRNAs, miRNAs mimics and 50- or 30-biotin covalently
linked miRNAs mimics or dsRNAs were manufactured by Shanghai
GenePharma Co., Ltd. dsP21-322 was used to activate p21 expres-
sion (positive control) and dsControl lacking signiﬁcant homology
to all known human sequences was used as a non-speciﬁc control
(Supplementary Table S1) [9,13].
2.4. Cell culture and transfection
Human BC lines T24 and EJ (ATCC) were maintained in
RPMI-1640 medium (Hyclone, USA) supplemented with 10% fetal
bovine serum (FBS) (Gibco, USA) in a humidiﬁed atmosphere of
5% CO2 at 37 C. The day before transfection, cells were plated in
growth medium at a density of 50–60%. Transfection of dsRNAs
and miRNA mimics was carried out by using Lipofectamine
RNAiMax (Invitrogen, USA) according to the manufacture’s proto-
col. The ﬁnal concentration of dsRNAs or miRNA mimics of each
well was 50nM.
2.5. RNA extraction, real-time PCR and miRNA analysis
Total RNA from cultured cells was isolated by using Trizol
reagent (Invitrogen, USA). 500 ng of total RNA was reverse tran-
scribed and real-time quantitative PCR was performed on the
Mx3000P system (Stratagene, USA) according to the manufac-
turer’s instructions. Mature miRNAs were reverse transcribed and
then quantitated. GAPDH and U6 snRNA were used as internal con-
trols for p21 and miRNAs, respectively. All primers (synthesized by
Invitrogen, USA) sequences used are available in Supplementary
Table S2. The PCR products were analyzed on 2% agarose gels
and visualized.
2.6. Protein isolation and western blot analysis
Whole-cell lysates, cytoplasmic and nuclear fractions were pre-
pared. Protein were separated by 10% SDS/PAGE and transferred
onto PVDF membranes (Millipore, USA). Membranes were incu-
bated with appropriate antibodies for 1 h at room temperature or
overnight at 4 C followed by incubation with a secondary anti-
body. The following antibodies were used: anti-p21 (Cell Signaling
Technology, USA) at 1:1000 dilution; anti-GAPDH, anti-Lamin B
(Boster, China) at 1:500 dilution.2.7. Immunoﬂuorescence
Attached cells were ﬁxed in 4% (v/v) formaldehyde and perme-
abilized with 0.5% (v/v) Triton X-100 (Sigma, USA). Cells were incu-
bated with 10% (v/v) goat serum (Boster, China) before incubation
with the primary anti-p21 antibody (Cell Signaling Technology,
USA) at dilution 1:400 in 1% BSA (Sigma, USA). After incubated
with the secondary antibody (FITC-conjugated goat anti-rabbit
IgG, 1:50 in PBS) (Boster, China) and DAPI, cells were examined
with Olympus (Japan) inverted ﬂuorescence microscope.
2.8. Chromatin immunoprecipitation (ChIP) assay
Cells transfected with biotin-labeled miRNAs were processed
for ChIP assay (Millipore, USA) at 72 h according to the manufac-
turer’s instructions with further modiﬁcations. Approximate
3  106 cells were used for one immunoprecipitation. Degradation
of miRNAs was avoided by RNase inhibitor (Thermo, USA) with a
ﬁnal concentration of 50 units/ml. Chromatins were Cross-linked
by 1% Formaldehyde (Sigma, USA) for 10 min at 37 C. Fixed cells
were washed and resuspended in SDS lysis buffer followed by son-
ication (30–35 sets of 5-second pulses with a 5 mm microtip at a
power setting of 30%). Chromations were precleared with Protein
A Agarose/Salmon Sperm DNA and immunoprecipitated overnight
at 4 C with antibodies of biotin (Santa Cruz Biotechnology, USA)
and IgG (Millipore, USA). Then the antibody/antigen/DNA complex
was collected and reverse cross-linked. DNA was column puriﬁed
(Omega bio-tek, USA) and used as template for real-time PCR.
Primers are available in Supplementary Table S2.
2.9. Senescence-associated b-galactosidase staining
Senescence was assessed by a senescence-associated b-galacto-
sidase assay (Sigma, USA). Brieﬂy, attached cells were washed and
ﬁxed. Cells were then stained at 37 C overnight. Photomicro-
graphs were captured using an Olympus (Japan) inverted light
microscope.
2.10. Cell cycle and Apoptosis analysis by Flow Cytometry
72 h after transfection, cells were ﬁxed by 70% cold ethanol at
4 C overnight. Then cells were incubated with RNase A (Sigma,
USA) at 37 C for 30 min and stained by propidium iodide (PI) (Key-
gen Biotech, China) staining solution at 4 C for 30 min. After stain-
ing, the cells were analyzed on a FACSort ﬂow cytometer (BD
Biosciences, USA). Distribution of cell cycle was showed as the per-
centage of cells in G0/G1, G2/M and S populations.
Apoptosis was assessed by ﬂow cytometry after co-staining of
cells with Annexin V-FITC and PI in accordance with manufac-
turer’s recommendations (BD Biosciences, USA). Annexin V FITC-
positive, PI negative cells and double-positive cells were consid-
ered to be in early and late stages of apoptosis, respectively.
2.11. Colony formation assay
Cells were harvested 24 h after transfection. 1000 cells were
seeded in new 6-wells and went on culture for 10 days without
any disturbance. The colonies were stained with 0.5% crystal violet
(Sigma, USA) and counted. The rate of colony formation was calcu-
lated as number of colonies/number of seeded cells.
2.12. Cell proliferation assay
Proliferation of cells was detected by the CellTiter 96AQueous
One Solution Cell Proliferation Assay kit (Promega, USA). 5000 cells
Fig. 1. Selected miRNAs targeting the p21 gene promoter and their expression pattern in BC tissues and cell lines. (A and B) Schematic representation of p21 promoter and
miR-103, miR-370, miR-1180 and miR-1236 target locations relative to TSS and the complementary sequences. (C) miRNAs expression levels in BC tissues and adjacent
normal controls via real-time quantitative PCR and standardized to U6 levels (n = 10). ⁄P < 0.01, ⁄⁄P < 0.001 compared to normal. (D) The relative expression of miRNAs in BC
cell lines via real-time quantitative PCR and standardized to U6 levels. ⁄P < 0.05, ⁄⁄P < 0.01, ⁄⁄⁄P < 0.001 compared to miR-103b. #P < 0.05, ##P < 0.01, ###P < 0.001 compared to
miR-370. &P < 0.01 compared to miR-1180. (E–H) The correlationships of 4 miRNAs (miR-103b, miR-370, miR-1180 and miR-1236) expression and p21 mRNA expression
levels in 10 pairs of the tumor and normal specimens. The results were detected by real-time PCR and normalized to U6 and GAPDH, respectively.
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measured at 5 points every 24 h from day 1 to day 5. At each time
point, culture medium of the 96-well plates was replaced by 10lL
Solution premixed with 100lL fresh medium. Followed by 2 h
incubation at 37 C, absorbance was determined by an absorbance
reader (Thermo, USA) at 490 nm.
2.13. Cell migration and invasion assay
The 24-well Boyden chamber with 8 lm pore size polycarbon-
ate membrane (Corning, USA) was used to analyze the cell motility.
For invasion assay, the membrane was pre-coated with matrigel(BD Biosciences, USA) to form a matrix barrier. 2  104 cells, trans-
fected with dsRNA or miRNA mimics for 72 h, were seeded on the
upper chamber with serum-free medium. Medium with 20% serum
was added to the lower chamber as a chemoattractant. The mem-
branes were ﬁxed at 24 h and stained with 0.5% crystal violet
(Sigma, USA). 5 visual ﬁelds of 200 magniﬁcation of each mem-
brane were randomly selected and counted.
2.14. Statistical analysis
The values were presented as mean ± standard deviation (SD).
The results were evaluated by SPSS version 13.0 software (SPSS
Fig. 2. Induction of p21 expression by miRNAs in BC cells. T24 and EJ cells were transfected with 50 nM of the indicated miRNAs or dsRNAs for 72 h. Mock sample was
transfected in the absence of miRNAs and dsRNAs. (A and B) Expression of p21 and GAPDHmRNA levels was assessed by real-time PCR. GAPDH served as a loading control. (C)
Induction of p21 protein expression in BC cells was detected by Western Blot analysis. GAPDH levels were set as loading control. (D and E) Densitometric analysis of p21
protein expression in BC cells. ⁄P < 0.05, ⁄⁄P < 0.01 and ⁄⁄⁄P < 0.001 compared to mock and dsControl group.
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among groups. The correlation between variables was analyzed
using Pearson correlation coefﬁcient. P values less than 0.05 were
considered statistically signiﬁcant.
3. Results
3.1. miRNAs predicted to target p21 promoter
To identify candidate miRNA(s) that may be involved in induc-
ing p21 expression, we scanned 1 kb of p21 promoter for sites
complementary to known human miRNAs. Several miRNAs were
identiﬁed under guidance of the stringent prediction strategy and
the arithmetic outcomes were further processed. At last, miR-
103b, miR-370-5p (miR-370), miR-1180-5p (miR-1180) and miR-
1236-3p (miR-1236) were selected for subsequent experiments
(Fig. 1A and B, Supplementary Table S3).
3.2. Expression patterns of the 4 selected miRNAs in BC tissues and cell
lines and correlations with p21
To analyze the expression patterns of the 4 candidate miRNAs
(miR-103b, miR-370, miR-1180 and miR-1236) in BC tissues, quan-
titative real-time PCR was conducted to measure their levelscompared to adjacent non-tumor tissues. It turned out that com-
pared with corresponding normal tissues, miR-103b expression
level in tumorous tissues was higher (without statistical signiﬁ-
cance), which is similar to previous study [14]. However, miR-
370, miR-1180 and miR-1236 exhibited a 1.85, 1.83 and 3.73-fold
reduction in tumorous tissues, respectively (Fig. 1C). Moreover, we
compared the relative expression levels of the 4 miRNAs among
themselves. As seen in Fig. 1D, miR-1236 was expressed lowest
in T24 and second to last in EJ cells. In addition, miR-370 decreased
most in EJ cells.
We further compared the expression levels of p21 mRNA
between BC and corresponding normal tissues. The mean value
of BC was lower than that of normal tissues, but no statistical sig-
niﬁcance was detected. Then we attempted to examine the corre-
lations between the expressions of the 4 miRNAs and p21 mRNA
from tissue samples. 3 of the 4 miRNAs (miR-370, miR-1180 and
miR-1236) levels positively correlate with p21 levels (Fig. 1E–H).
Based on these results, miR-370, miR-1180 and miR-1236 may
act as tumor suppressors in BC.
3.3. Overexpression of miRNAs activates p21 expression
To identify candidate miRNA(s) that may be involved in posi-
tively regulating p21 expression, synthetic miRNAs mimics of the
Fig. 3. Subcellular expression of p21 protein after transfection of miRNAs. T24 and EJ cells were transfected with 50 nM of the indicated miRNAs or dsRNAs for 72 h. Mock
sample was transfected in the absence of miRNAs and dsRNAs. (A) Subcellular expression of p21 protein (green) was evaluated by Immunoﬂuorescence in T24 and EJ cells
(400). The nucleus were stained with DAPI (blue). (B) p21 in the nuclear fraction and cytoplasmic fraction was detected by Immunoblot in T24 and EJ cells. Lamin B and
GAPDH were used for as the internal controls, respectively. (C) The ratio of nuclear fraction (n)/cytoplasmic fraction (c) of p21 protein expression after infection in T24 and EJ
cells was assessed by densitometric analysis. ⁄P < 0.05, ⁄⁄P < 0.01 compared to mock and dsControl group.
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were transfected into T24 and EJ cells. PCR analysis showed that
miRNAs and dsRNAs were highly expressed after transfection (Sup-
plemental Fig. S1). Compared to control treatment, dsP21-322,
miR-370, miR-1180 and miR-1236 led to a 5.53-, 4.33-, 4.09- and
5.57-fold induction of p21 mRNA levels 72 h after transfection in
T24 cells, respectively (Fig. 2A). They caused a 4.63-, 5.56-, 5.18-
and 5.48-fold induction in EJ cells, respectively (Fig. 2B). Moreover,
this induction was further conﬁrmed by immunoblot analysis inT24 and EJ cells (Fig. 2C–E). However, miR-103b failed to upregu-
late p21 expression at neither the p21 mRNA nor protein levels
in T24 and EJ cells (Fig. 2A–E).
3.4. Overexpression of miRNAs mainly induces nuclear p21 protein
expression
p21 has been shown to be a tumor suppressor or an oncogene
depending on its subcellular location. We performed immunoﬂuo-
Fig. 4. Speciﬁc binding of biotinylated miRNAs to the p21 promoter. Cells were transfected with 50 nM of biotinylated miRNAs or dsControl for 72 h. The anti-biotin antibody
was used to pull down miRNAs associated DNA. The resulted DNA was ampliﬁed by real-time PCR with corresponding primer sets and normalized to input levels. IgG was
used as a negative antibody. (A) Schematic illustration of the primers capable of amplifying the miRNAs targeted sequences of p21 promoter at different regions. Locations are
shown relative to the TSS. (B–D) ChIP assay veriﬁes miRNAs enrichment at their target regions of p21 promoter in T24 cells. (E–G) ChIP assay identiﬁes enrichment of miRNAs
at their target regions of p21 promoter in EJ cells. ⁄P < 0.05, ⁄⁄P < 0.01 and ⁄⁄⁄P < 0.001 compared to corresponding dsControl group.
C. Wang et al. / FEBS Letters 588 (2014) 4654–4664 4659rescence staining to examine p21 subcellular location induced by
miR-370, miR-1180 and miR-1236 transfection at 72 h in T24 and
EJ cells. As shown in Fig. 3A, the 3 miRNAs and dsP21-322 signiﬁ-
cantly induced nuclear p21 expression. To further verify this result,
the subcellular protein was detected by immunoblot. Compared to
mock and dsControl transfection, the miRNAs induced p21 expres-
sion mainly in the nucleus rather than cytoplasm (Fig. 3B–D).
3.5. miRNAs interact directly with p21 promoter
We and others have reported that the binding of miRNAs or
dsRNAs to promoter is one of the possible mechanisms to activate
speciﬁc gene expression [8,13,15]. To explore whether the 3 miR-
NAs interact directly with p21 promoter, we performed ChIP assay
via biotinylated miRNAs which were predicted to target the p21
promoter. The biotin was covalently linked to either 50-end or 30-
end of miRNAs and dsControl antisense. After 72 h with individu-
ally transfection of the 3 miRNAs or dsControl, the target promoter
DNA was pulled down by using a well-characterized biotin anti-
body and then ampliﬁed by real-time PCR with speciﬁc primers.
As shown in Fig. 4A, the 3 sets of primers were used to amplify pro-
moter DNA sequences ranging from 630 to 503, 407 to 270
and 272 to 27 relative to transcription starting site (TSS),
respectively. Finally, all 3 of the biotin labeled miRNAs pulled
down promoter DNA more effectively than the dsControl RNA both
in T24 (Fig. 4B–D) and EJ cells (Fig. 4E–G). These results indicate
that the selected miRNAs interact directly with p21 promoter.3.6. miRNAs induces cycle arrest and apoptosis in BC cell lines by
inhibiting downstream genes of p21
To further verify the role of p21 activated by miRNAs and
dsP21-322 on cell cycle regulation, we ﬁrst examined the down-
stream genes’ mRNAs expression of p21. The CDK4/6 and Cyclin
D1 expressions were inhibited after miR-370, miR-1180, miR-
1236 and dsP21-322 transfection in T24 and EJ cells (Fig. 5A).
Then we analyzed the DNA content of PI-stained cells using
ﬂow cytometry analysis to measure cell cycle distribution. Results
revealed a signiﬁcant accumulation of cells in G0/G1 after transfec-
tion of miR-370, miR-1180, miR-1236 and dsP21-322 compared to
mock or dsControl treatment (Fig. 5B and C). These results are in
agreement with previous studies in which p21 would induce G1
arrest [16].
Subsequently, we investigated whether miRNAs induced p21
upregulation would induce cellular apoptosis. In consistent with
our speculation, overexpression of miR-370, miR-1180, miR-1236
and dsP21-322 increased apoptosis at both early and late stage
in T24 and EJ cells, as measured by ﬂow cytometry for PI and
Annexin V staining (Fig. 5D–F).
3.7. miRNAs induce cell senescence and inhibit BC cell proliferation
To evaluate the effect of p21 activation by miRNAs on cell
senescence, we measured senescence-associated b-galactosidase
activity and found a marked increase of positive b-galactosidase
Fig. 5. miRNAs overexpression inhibits downstream genes expression of p21 and induces cells apoptosis. T24 and EJ cells were transfected with 50 nM of the indicated
miRNAs, dsRNAs or mock transfected for 72 h. (A) Expression of CDK4/6 and Cyclin D1 was detected by standard RT-PCR. GAPDH served as a loading control. (B and C) Cell
cycle distribution was conducted using ﬂow cytometry with PI stained. ⁄P < 0.05, ⁄⁄P < 0.01 and ⁄⁄⁄P < 0.001 compared to mock and dsControl group. (D) Representative ﬂow
cytometry images of cell apoptosis. Cells that stained positive for Annexin V-FITC and negative for PI were undergoing early stage of apoptosis; Cells that stained positive for
both Annexin V-FITC and PI were in the end stage of apoptosis. (E and F) Percentage of early and late apoptotic cells was shown by histogram. ⁄P < 0.001, #P < 0.001 compared
to mock and dsControl group.
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transfection (Fig. 6A).
In order to substantiate the cell growth mode after p21 activa-
tion by miRNAs, we carried out the colony formation assay. Appar-ently, the 3 miRNAs and dsP21-322 presented an effect of
suppressing the colony formation ability of T24 and EJ cells
(Fig. 6B). Moreover, compared with mock and dsControl group,
the colony formation rates of the cells transfected with 3 miRNAs
Fig. 6. Overexpression of miRNAs induces cell senescence and inhibits cell proliferation. T24 and EJ cells were transfected with 50 nM of the indicated miRNAs, dsRNAs or
mock transfected. (A) Induction of cellular senescence by miRNAs or dsP21-322 overexpression. Cellular senescence was measured by b-galactosidase assay (400). (B)
Representative photographs of the colony formation assay. (C and D) Quantiﬁcation of the cell colonies formation. ⁄P < 0.05, ⁄⁄P < 0.01 compared to mock and dsControl group.
(E and F) Viable cells were measured from day 1 to 5 following transfection using the CellTiter 96AQueous One Solution Cell Proliferation Assay kit. Results were plotted as OD
values. ⁄P < 0.05; ⁄⁄P < 0.01; ⁄⁄⁄P < 0.001 reveals the corresponding group compared to mock transfection at the same time point.
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observe the growth inhibitory function of above 3 miRNAs, we
used cell viability assay to assess the proliferation ability in both
of the BC lines for 5 days following transfection. Indeed, 3 miRNAs
stably decreased cell proliferation at 4 days later (Fig. 6E and F).3.8. miRNAs inhibit BC cell migration and invasion
As we know, p21 can inhibit tumor cells’ ability in migration
and invasion [17]. To determine whether miRNAs induced p21
activation has the effect on inhibiting BC cells migration, migration
chamber assay was used after artiﬁcial expression of miRNAs at
Fig. 7. Forced expression of miRNAs suppresses BC cells migration and invasion. T24 and EJ cells were transfected with 50 nM of the indicated miRNAs, dsRNAs or mock
transfected. Cell migration and invasion were evaluated after 24 h incubation by transwell assay. (A) Representative photographs of transwell assay (200). (B and C) Number
of migrated and invaded cells were quantiﬁed in 4 random images from each treatment group. Results are plotted as percent (%) relative to mock group. ⁄P < 0.01, ⁄⁄P < 0.001,
#P < 0.01, ##P < 0.001 compared to mock and dsControl group.
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cells were ﬁxed, stained and documented. As the representative
micrographs demonstrated, miR-370, miR-1180 and miR-1236
overexpression led to potent inhibition of cell migration (Fig. 7).
Likewise, invasion capability of BC cells transfected with miR-
NAs and dsRNAs was evaluated by Matrigel invasion chamber
assay. As expected, miR-370, miR-1180, miR-1236 mimics and
dsP21-322 in T24 and J82 can notably repress their invasion ability
compared with mock and dsControl groups (Fig. 7).
3.9. miR-1236 inhibit BC cells mainly by upregulating p21
We next investigated whether p21 was mainly responsible for
tumor suppression after miRNAs transfection. We addressed this
by using RNA interference (siP21) to knockdown the expression
of p21 in T24 and EJ cells (Supplementary Table S1) [18]
(Fig. 8A). The miR-1236 was included in this experiment as its
expression was the lowest out of the 4 candidate miRNAs in BC tis-
sues, The results showed that depletion of p21 expression signiﬁ-
cantly abrogated G0/G1 cycle arrest (Fig. 8B), restored the ability
of colony formation (Fig. 8C and D) and cell proliferation (Fig. 8Eand F) mediated by miR-1236. These data together demonstrated
that miR-1236 inhibited BC cells largely depended on regulating
p21.
4. Discussion
In the present work, we identiﬁed 3 miRNAs (miR-370, miR-
1180 and miR-1236) which are lower expressed in BC tissues than
paired normal bladder tissues. Moreover, their levels positively
correlate with p21 mRNA expression in BC. The 3 miRNAs readily
induce human p21 gene expression by targeting the predicted sites
in p21 promoter. Mechanistically, this gene activation depends on
miRNAs binding the p21 promoter sequences. Furthermore, we
demonstrated that several downstream genes of p21, such as
CDK4/6 and Cyclin D1 are downregulated after 3 miRNAs transfec-
tion and consequently suppress BC cells. In addition, the anti-
tumor function of miR-1236 is mainly achieved by modulating
p21.
miRNAs were reported to play essential roles in carcinogenesis
and regulate signal transduction pathway in BC [19]. Complemen-
tary sequence is one of the prerequisites of miRNAs suppression or
Fig. 8. miR-1236 inhibits BC cells mainly by upregulating p21. T24 and EJ cells were transfected with 50 nM of the indicated miRNAs, dsRNAs or mock transfected for 72 h. (A)
p21 mRNA expression detected by standard RT-PCT. GAPDH served as a loading control. (B) Cell cycle distribution was conducted using ﬂow cytometry with PI stained.
⁄P < 0.05 and #P < 0.05 compared to dsControl group, ⁄⁄P < 0.01 and ##P < 0.01 compared to miR-1236. (C) Representative photographs of the colony formation assay. (D)
Quantiﬁcation of the cell colonies formation. ⁄P < 0.01 and ⁄⁄P < 0.001 compared to dsControl group, #P < 0.01 and ##P < 0.001 compared to miR-1236. (E and F) Viable cells
were measured from day 1 to 5 following transfection using the CellTiter 96AQueous One Solution Cell Proliferation Assay kit. ⁄P < 0.05; ⁄⁄P < 0.01; ⁄⁄⁄P < 0.001 reveals the
corresponding group compared to dsControl transfection at the same time point.
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promoter [8,20]. However, even stringent complementarity would
not always reveal bona ﬁde miRNAs target recognition without
experimental validation [21]. Hereby, we identiﬁed 4 miRNAs
(miR-103b, miR-370, miR-1180 and miR-1236) with sites highly-
complementary to p21 promoter sequences [22]. Of the 4 miRNAs,
3 (miR-370, miR-1180 and miR-1236) were validated to activate
p21 expression. As noted above, miR-103b failed to activate p21
expression even with a higher complementary score which might
due to the fact that different target locations had different thermo-
dynamic properties, chromatin/DNA accessibility and distance
from TSS [23]. This suggested that besides sequence complemen-
tarity, additional elements are required for p21 gene activation [8].
The mechanism underlying miRNAs mediated p21 induction
remains elusive. However, the Argonaute protein is required to
load miRNAs in the cytoplasm and then form an active Argona-
ute–RNA complex. Under the guide of miRNAs, the complex thenenters the nucleus and binds to gene promoter. Afterwards,
histone modifying enzymes are recruited to the promoter to acti-
vate transcriptional expression through epigenetic modiﬁcations
[8,24–26].
p21 is a well-known tumor suppressor by controlling cell cycle,
inducing apoptosis and senescence [11], and attenuating cell
migration and invasion [27]. Our data show that p21 activated
by miRNAs/dsP21-322 promotes BC cells senescence, G1 arrest
and apoptosis. Moreover, it inhibits cells colony formation and pro-
liferation, and represses migration and invasion. The effect of p21
upregulation on BC cells in the present research is in line with pre-
vious reports [28–30]. Most notably, p21 has different function
based on its subcellular localization. p21 behaves mainly as a
tumor suppressor when assembles in the nucleus, whereas as an
oncogene when in the cytoplasm [10]. Our results show endoge-
nous miRNAs principally induce nuclear p21 by targeting the pro-
moter and exerted the anti-tumor inﬂuence.
4664 C. Wang et al. / FEBS Letters 588 (2014) 4654–4664BC can be caused by a variety of genetic alternations, and p21
loss-of-function mutation is one of the most important [31]. As
research advances, more and more miRNAs were found abnormally
expressed in BC. Thus it is increasingly accepted that miRNAs
manipulation might help in tumor eradication [3,14,32]. Unlike
traditional miRNAs’ functional modes, the 3 miRNAs included in
present study are able to activate p21 by targeting its promoter
at different regions. This manifests that p21 can be activated by
diverse miRNAs at diverse sites of the promoter. Therefore, it pro-
vides an additional alternative to regulate genes responsible for BC
and expands miRNAs application.
5. Conclusion
In conclusion, our study provides evidence that miRNAs medi-
ated expression of p21 by targeting its promoter has anti-tumor
function in BC cell lines. Nevertheless, further research is needed
to elucidate the mechanism by which miRNAs directly activate
gene expression and suppress cancer.
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